Cedar Hill, TX, United States of America

John J Nemunaitis

This inventor holds 17 USPTO granted patents and 16 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Gradalis, Inc., Strike Bio, Inc., Baylor College of Medicine. Active years: 2013-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John J Nemunaitis. Retrieved from https://idiyas.com/inventor/john-j-nemunaitis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 16)

% Patents Active = 70.6

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 3.7

ph-index = 5

Forward Citations = 64(Granted Patents)

Location History:

Dallas, TX (US) (2014)
Cedar Hill, TX (US) (2013 - 2019)
Carrollton, CA (US) (2022)

Company Filing History:

Baylor College of Medicine

patents

where one patent can have more than one assignee

Years Active: 2013-2022

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11400170 - Methods for treating cancers (2022-08-02),

2. 10253331 - Furin-knockdown and GM-CSF-augmented (FANG) cancer vaccine (2019-04-09),

3. 9914977 - Individualized cancer therapy (2018-03-13),

4. 9790518 - Furin-knockdown and GM-CSF-augmented (FANG) cancer vaccine (2017-10-17),

5. 9695422 - Furin-knockdown bi-functional RNA (2017-07-04),

6. 9683237 - Multiple targeted RNAI for the treatment of cancers (2017-06-20),

7. 9528991 - Individualized cancer therapy (2016-12-27),

8. 9382589 - Individualized cancer therapy (2016-07-05),

9. 9353373 - [object Object] (2016-05-31),

10. 9273300 - Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy (2016-03-01),

11. 9157084 - Furin-knockdown bi-functional RNA (2015-10-13),

12. 9133459 - Therapeutic RNA interference technology targeted to the PDX-1 oncogene in PDX-1 expressing neuroendocrine tumors (2015-09-15),

13. 9132146 - Furin-knockdown and GM-CSF-augmented (FANG) cancer vaccine (2015-09-15),

14. 8916530 - Individualized cancer therapy (2014-12-23),

15. 8906874 - Bi-functional shRNA targeting Stathmin 1 and uses thereof (2014-12-09),

Title: The Innovative Mind of John J. Nemunaitis: Pioneering Cancer Treatments

Introduction

John J. Nemunaitis is a prominent inventor based in Cedar Hill, Texas, known for his groundbreaking work in the field of oncology. With a portfolio that includes 17 patents, Nemunaitis is committed to innovating treatment options for cancer patients, particularly in the realm of ovarian cancer.

Latest Patents

Nemunaitis's most recent patents focus on advanced methods for treating cancers. One of the key inventions involves compositions and methods for preventing ovarian cancer recurrence and treating BRCA1/2 wild-type ovarian cancer. The patented method details the use of an autologous tumor cell vaccine, which comprises genetically modified cells for furin knockdown alongside GM-CSF expression. In some embodiments, the method suggests administering an autologous tumor cell vaccine before a combination therapy that includes both the vaccine and atezolizumab. Additionally, he has developed a furin-knockdown and GM-CSF-augmented (FANG) cancer vaccine, aimed at enhancing tumor antigen expression, presentation, and processing while reducing immunosuppressive activities.

Career Highlights

Throughout his career, John J. Nemunaitis has made significant contributions to cancer research and treatment. His innovative approaches have led to advances in vaccine technology, giving hope to many patients battling cancer.

Collaborations

Nemunaitis has worked with various reputable organizations in the biotechnology field, including Gradalis, Inc. and Strike Bio, Inc. He has also collaborated closely with notable colleagues such as Donald Rao and Neil Senzer, contributing his expertise toward the development of novel cancer therapies.

Conclusion

John J. Nemunaitis stands out as an influential inventor in oncology, dedicated to improving patient outcomes through his innovative patents. His continued research and collaboration with industry leaders promise to pave the way for new treatment modalities in the fight against cancer. With a strong focus on integrating cutting-edge technology into cancer therapies, Nemunaitis exemplifies the spirit of innovation that drives progress in medical science.

Profile summary based on public USPTO records.